Summary of Teknova's Q4 2025 Earnings Call

1Key Financial Results and Metrics

Q4 2025 Revenue: $10.0 million, an 8% increase from $9.3 million in Q4 2024.

Full Year 2025 Revenue: $40.5 million, a 7% increase from $37.7 million in 2024.

Gross Profit: Q4 gross profit was $3.2 million (32.5% margin), up from $2.1 million (23.0% margin) in Q4 2024. Full year gross profit was $13.4 million (33.2% margin), up from $7.2 million (19.2% margin) in 2024.

Net Loss: Q4 net loss was $4.8 million ($0.09 per share), improved from a loss of $5.7 million ($0.11 per share) in Q4 2024. Full year net loss was $17.3 million ($0.32 per share), down from $26.7 million ($0.57 per share) in 2024.

Adjusted EBITDA: Negative $1.8 million in Q4 2025, an improvement from negative $3.2 million in Q4 2024. Full year adjusted EBITDA was negative $6.7 million, improved from negative $14.5 million in 2024.

Free Cash Flow: Negative $9.8 million for the full year, better than the guidance of less than $12 million.

2Strategic Updates and Business Highlights

Customer Growth: Active clinical customers increased to 60, a 25% rise from 2024, with notable growth in therapies supported.

Product Segments: Revenue from catalog products grew by low double digits; Clinical Solutions revenue rose 47% in Q4 2025.

Operational Efficiency: Achieved 95% on-time delivery and improved manufacturing efficiencies contributed to better gross margins.

Investment in Growth: Plans to invest $2 million annually in commercial capabilities to enhance market presence and accelerate revenue growth.

3Forward Guidance and Outlook

2026 Revenue Guidance: Expected total revenue of $42 million to $44 million, implying approximately 6% growth compared to 2025.

Long-term Growth: Anticipated sustainable revenue growth of 20% to 25% over the longer term, with an adjusted EBITDA positive target by the end of 2027.

Market Recovery: Positive indicators from biotech funding in Q4 2025 may lead to increased revenue in 2026, particularly in the custom biopharma segment.

4Bad News, Challenges, or Points of Concern

Declining Average Revenue per Customer: Average revenue per customer decreased due to the addition of new customers, particularly in early-stage therapies.

Market Uncertainty: Cautious outlook for 2026 due to the need for sustained biotech funding and a lack of larger orders from Clinical Solutions customers.

Operational Risks: High fixed costs associated with operations may lead to variability in revenue recognition and cash flow.

5Notable Q&A Insights

Emerging Markets: Discussion on growth potential in sequencing, spatial genomics, and cancer screening, with a focus on increasing commercial investments to capture these opportunities.

Customer Transition: Clarification on the revenue step-up for customers transitioning from RUO to GMP, with significant increases expected as therapies progress through clinical phases.

FDA Guidance Impact: Potential for shorter drug development timelines could benefit Teknova, especially if therapies supported by the company reach commercialization faster.

Cell and Gene Therapy Revenue: 24% of total revenue in 2025 came from cell and gene therapy-related customers, consistent with 2024. Overall, Teknova reported solid growth in 2025, with strategic investments aimed at enhancing future performance, although challenges remain in customer revenue dynamics and market conditions.